Role of 5-HT2C receptors in the enhancement of c-Fos expression induced by a 5-HT2B/2C inverse agonist and 5-HT2 agonists in the rat basal ganglia
Exp Brain Res. 2013-05-17; 230(4): 525-535
Lire sur PubMed
1. Exp Brain Res. 2013 Oct;230(4):525-35. doi: 10.1007/s00221-013-3562-9. Epub 2013
Role of 5-HT2C receptors in the enhancement of c-Fos expression induced by a
5-HT2B/2C inverse agonist and 5-HT 2 agonists in the rat basal ganglia.
Navailles S(1), Lagière M, Le Moine C, De Deurwaerdère P.
(1)Université de Bordeaux, Bordeaux Cedex, France.
Some non-selective serotonin2C (5-HT2C) agonists or inverse agonists enhance the
product of the proto-oncogene c-Fos within the basal ganglia, a group of brain
regions involved in motor behavior and in the ability of these drugs to promote
abnormal movements. The role of 5-HT2C receptors in these effects is unclear. The
5-HT2C antagonist SB243,213 (1 mg/kg), which enhanced Fos per se in the striatum
and the subthalamic nucleus (STN) only, was used to study the implication of
5-HT2C receptors. The agonists Ro 60-0175 (3 mg/kg) and m-CPP (1 mg/kg) and the
inverse agonist SB206,553 (10 mg/kg) enhanced Fos expression in the STN and
faintly in the entopeduncular nucleus (EPN, the internal globus pallidus in
primate). The effects of these drugs differed mainly in the striatum regarding
the magnitude (m-CPP > Ro 60-0175> SB243,213 > SB206,553) or the striatal
quadrants (faint to no labeling in lateral striatum) and in the substantia nigra.
None of these compounds enhanced Fos expression by themselves in the globus
pallidus or in the EPN when combined with SB243,213. Their Fos effect in the STN
was reduced significantly by SB243,213 only in the case of m-CPP. In the
ventromedial striatum, SB243,213 reduced the effects of m-CPP while SB206,553
reduced the effects of SB243,213. The results show that opposite pharmacological
agents alter similarly Fos expression in the EPN or the STN. Although some of the
effects of 5-HT agents are related to targets other than 5-HT2C receptors, the
study confirms the existence of multiple 5-HT2C receptor-dependent controls
recruited by these drugs upon basal ganglia activity.
PMID: 23681297 [Indexed for MEDLINE]